TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01299610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 2.0%
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 2.0%
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 0.2%
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 0.2%
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 0.05%
Description: White cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 0.05%
Description: White cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to slightly colored opaque cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to slightly colored opaque cream
Study: NCT00804843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin/niacin extended-release
Description: 80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: (Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: (Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
Study: NCT02543502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: treatment of periodontal cleaning
Study: NCT00459641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Bone marrow aspirate or steroids
Study: NCT02770885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
Study: NCT04359576

Intervention type: DIAGNOSTIC_TEST
Intervention: Primary and secondary hemostasis
Description: Focus on platelet aggregation, primary and secondary hemostasis parameters
Study: NCT03270059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study: NCT01280409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
Study: NCT02423356

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
Study: NCT02899377

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT Imaging
Description: pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-MET PET/CT Imaging
Description: Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-MET PET/CT Imaging
Description: Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Imaging with intravenous contrast with gadoterate meglumine
Description: Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Imaging with intravenous contrast with gadoterate meglumine
Description: Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minor Salivary gland (labial) biopsy
Description: A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
Study: NCT04320277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
Study: NCT04391972

Intervention type: DEVICE
Group type: OTHER
Intervention: SAV
Description: SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
Study: NCT01771536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Study: NCT00435994

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled primatene will be given as a breathing treatment
Description: While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled primatene will be given as a breathing treatment
Description: While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Washing
Description: 1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Washing
Description: 1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Washing
Description: 1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
Study: NCT03096444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline Hydrochloride
Description: 2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride
Description: 2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipoderm Cream
Description: 2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
Study: NCT02818127

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
Study: NCT04001309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions
Description: Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
Study: NCT00977730

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protandim
Description: 1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
Study: NCT03476863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment Maneuver
Description: Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mechanical ventilation
Description: Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
Study: NCT03898518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week jump rope exercise program
Description: Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
Study: NCT00260169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care treatment
Description: Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
Study: NCT03170427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance cardiography
Description: hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Impedance cardiography
Description: hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory levels
Description: Sensory levels are checked using ice test cold

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sensory levels
Description: Sensory levels are checked using ice test cold

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor block
Description: motor block is measured by modified Bromage scale

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Motor block
Description: motor block is measured by modified Bromage scale
Study: NCT03270059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01510977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: Immediately after first colonoscopy failure, polyethylene glycol 2L addition
Study: NCT03230617

Intervention type: DEVICE
Intervention: Mechanical ventilator
Description: Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.

Intervention type: DEVICE
Intervention: Mechanical ventilator
Description: Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
Study: NCT01646398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
Study: NCT03705312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair
Description: Transcatheter mitral valve repair performed using the MitraClip device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Guideline-directed medical therapy
Description: Standard medical therapy for heart failure as recommended by HF guidelines
Study: NCT02485548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Patients will receive IMRT and concurrent raltitrexed and cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Patients will receive IMRT and concurrent 5-Fu and cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: All patients will receive concurrent cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: All patients will receive concurrent cisplatin.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: All patients will receive IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: All patients will receive IMRT
Study: NCT04087408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial
Description: 1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU.
Study: NCT03943108

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
Study: NCT01915108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
Study: NCT02522650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: 5mg twice a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamterene
Description: 50mg twice a day for 8 weeks
Study: NCT03246555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan or Fimasartan/Hydrochlorothiazide
Description: The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril or Perindopril/Indapamide
Description: The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.